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Cryopreserving and 
deglycerolizing sickle cell trait 
red blood cell components using 
an automated cell-processing 
system
r.J. acKley, a.H. lee-StrOKa, B.J. Bryant, d.F. StrOnceK, and K.M. Byrne
RBC components with rare phenotypes are sometimes re-
quired for patients with sickle cell disease, and these rare 
components can often be found among donors with sickle 
cell trait.  Cryopreserving RBC components from sickle cell 
trait donors requires a modified deglycerolization method 
to preserve the integrity of the RBCs.  This study evaluated 
the feasibility of using an automated cell-processing system 
to cryopreserve and deglycerolize sickle cell trait donor RBC 
components.  CP2D/AS-3 RBC components were collected 
from three donors with sickle cell trait.  Each component was 
processed with an automated cell-processing system (ACP 215, 
Haemonetics Corp., Braintree, MA) and cryopreserved within 
6 days of collection.  The components were stored at –65°C 
or less for at least 2 days and were deglycerolized using the 
automated cell-processing system’s standard procedure.  Before 
cryopreservation and after deglycerolization, several variables 
were measured.  Deglycerolization resulted in recovery of 43.0, 
76.5, and 67.5 percent of RBCs from the three sickle-cell-trait 
donor components compared with 80 percent or greater for 
all six control components.  A small, dark red, jelly-like mass 
was noted in the bowl of the disposable set after deglycero-
lization of each of the three RBC sickle cell trait components. 
The osmolalities of all three sickle cell trait components were 
less than 400 mOsm/kg, but only one of the three was ac-
ceptable for a 14-day outdate.  Freezing and deglycerolization 
of sickle cell trait donor RBC components with the automated 
cell-processing system resulted in recovery of some RBCs, but 
a decrease in RBC recovery was problematic.  Modifications of 
the procedure are needed for processing sickle cell trait donor 
RBC components.  Immunohematology 2008:24:107–111.
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Patients with sickle cell disease (SCD) often 
require RBC transfusions throughout their lifetimes. 
These patients are exposed to blood from multiple 
donors and have an increased chance of forming 
alloantibodies.  According to one study, transfused 
patients with SCD have up to a 29 percent chance 
of becoming alloimmunized.1  This immunization 
occurs because the majority of RBC transfusions are 
obtained from Caucasian donors and subsequently 
result in exposure to major differences in antigens.2
Because of the differing hospital protocols 
concerning the matching of RBC blood group phe-
notypes of patients with SCD and RBC component 
donors, these patients may receive RBC components 
that have only been matched for ABO and D blood 
group antigens.  Osby and Shulman3 report results 
of a survey that indicate 62.9 percent of hospitals 
crossmatch only ABO/D-compatible blood whereas 
27.9 percent determine the patient’s baseline phe-
notype for commonly immunogenic antigens and 
crossmatch ABO/D-compatible and phenotypically 
matched RBC units.  Alternatively, 9.2 percent of 
hospitals report that the patient’s baseline phenotype 
for common antigens is determined, but crossmatch 
only ABO/D-compatible RBC units initially.3  After 
an antibody is made, all subsequent RBC units trans-
fused are antigen matched.  Initiation of transfusion 
of phenotypically matched RBC units only after im-
munization occurs is based on the observation that 
some patients develop alloantibodies after relatively 
few RBC transfusions and are referred to as “re-
sponders” whereas others may be “nonresponders” 
who may not make antibodies even after multiple 
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transfusions with RBCs matched only for ABO and 
D blood group antigens.1
The risk of alloimmunization of patients with 
SCD may make it difficult to find phenotypically 
compatible RBC components for transfusion.  Some 
patients need RBC components from donors with 
unusual phenotypes that can only be found in reposi-
tories of cryopreserved RBC components with rare 
phenotypes.  The probability of finding compatible 
components for patients with SCD is higher among 
donors who are African or of African descent, who 
are more likely to have similar RBC phenotypes.4
Blood donors who are likely to have RBCs phe-
notypically compatible with those of patients with 
SCD are also at risk to be heterozygous for the gene 
encoding hemoglobin S (HbS) and thus be HbS/HbA. 
The donor population that expresses heterozygosity 
for the gene encoding HbS has sickle cell trait, but 
is healthy.  However, collecting and preparing RBC 
components from donors with sickle cell trait pre-
sents two difficulties.  The first is filter failure, which 
can be defined as the inability to remove a sufficient 
number of leukocytes, and the second is the clot-
ting of the blood inside the filter.  Neither of these 
outcomes is inevitable, but one study found that ap-
proximately half of the RBC components collected 
from people with sickle trait occlude WBC-reduction 
filters, one quarter pass completely through the filter 
but the quantity of WBCs remaining exceeds criteria 
for WBC reduction, and only one quarter are ef-
fectively filtered.5  Polymerization of HbS during the 
collection and processing of the blood is responsible 
for the occlusion of leukocyte-reduction filters, but 
this problem can be reduced by the collection of 
RBC components by apheresis.6
The second problem is RBC cryopreservation. 
Unless a modified method described by Meryman 
and Hornblower7 is used, the deglycerolization pro-
cess exposes RBCs to hyperosmotic saline, which 
produces extreme hemolysis of sickle cell trait donor 
RBCs and yields a dark red, jelly-like mass rather 
than a suspension of RBCs.  The standard deglyc-
erolization procedure used with a semiautomatic cell 
washer involves dilution of the thawed cells with 
12% saline followed by dilution with 1.6% saline and 
washing with 0.8% saline plus 0.2% glucose.8  The 
modified procedure involves dilution of the thawed 
cells in 12% saline followed by dilution in a large 
volume of 0.8% saline plus 0.2% glucose followed by 
washing in 0.8% saline plus 0.2% glucose.7 
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The Meryman and Hornblower method,7 
however, was described for use with traditional 
processing,which involves an open system.  When 
an open system is used, once the RBC components 
are thawed and deglycerolized, they expire within 
24 hours.  This short shelf-life can result in the 
loss of RBC components with rare phenotypes if 
they are unable to be transfused within 24 hours. 
However,allowances do exist to refreeze rare donor 
units one time.2
Recently, the FDA has approved an automated 
bloodprocessing system, ACP 215, to freeze and 
deglycerolize RBC components.9,10  This instrument 
is a functionally closed system conferring a 14-day 
outdate on the component.  In addition, deglycerol-
ization of RBCs with the automated blood-processing 
system involves dilution in 12% saline and washings 
in 0.9% saline plus 0.2% glucose.9,10  Inasmuch as 
these deglycerolization solutions were similar to 
those described by Meryman and Hornblower,7 we 
hypothesized that the ACP 215 may allow for the 
successful deglycerolization of sickle cell trait donor 
RBC components.  This study assessed the feasibility 
of using the ACP 215 for the cryopreservation and 
deglycerolization of RBC components from donors 
with sickle cell trait.
Materials and Methods
Study Design
Donors with sickle cell trait were recruited from 
a population of healthy people who regularly donate 
blood for research studies at our institution, and 
informed consent was obtained before the blood 
was collected.  Whole blood units were collected 
and processed into nonleukoreduced RBC compo-
nents from three donors with sickle cell trait, and 
each component was processed with an automated 
cell-processing system (ACP 215, Haemonetics Corp., 
Braintree, MA) and cryopreserved within 6 days of 
collection.  Although the ACP 215 is not approved 
for processing CP2D/AS-3 nonleukoreduced RBCs, 
leukoreduction was not performed in this study to 
avoid filter failure and loss of sickle trait units.  The 
components were stored at –65°C or less for at least 
2 days and were deglycerolized using the ACP 215’s 
standard procedure.  Before cryopreservation and 
after deglycerolization, several variables were mea-
sured including weight, hematocrit, and supernatant 
hemoglobin levels.  Data from RBC components col-
lected from six healthy routine blood donors without 
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sickle cell trait were collected and used as controls. 
These control units were cryopreserved, thawed, 
and deglycerolized using the same automated cell-
processing system.  All the donors met the AABB 
criteria for donating whole blood.  The study was 
approved by the institutional review board.
Study Population
Blood from three donors with sickle cell trait 
was studied.  Donor 1 was a 23-year-old woman 
with a mixed ethnic background.  Donor 2 was a 
59-year-old Black woman.  Donor 3 was a 37-year-old 
Black woman.  The control units were collected from 
healthy donors ranging from 50 to 61 years of age. 
Four of the control donors were men and two were 
women.  All were Caucasian.
Collection and Processing of RBC Units
A unit of whole blood was collected using a stan-
dard collection method for whole blood drawn into a 
CP2D/AS-3 triple blood bag set with an in-line filter 
and Y sampling site (Pall Corporation, East Hill, NY). 
Within 4 hours of collection, the whole blood was 
spun down and plasma was expressed off the unit.
The in-line leukocyte filter was then removed 
using a heat sealer (Composeal Mobilea, Fresenius 
HemoCare, Redmond, WA), and the tubing was re-
joined to the bag containing the AS-3 using a sterile 
connecting device (SCD sterile tubing welder, Terumo 
Medical Corporation, Somerset, NJ).  Next, the AS-3 
was added to the packed RBCs without leukocyte 
filtration.  The RBC component was then refrigerated 
at 1° to 6°C for at least 2 days before freezing.
Cryopreservation
The AS-3 RBC components were centrifuged 
and the supernatant removed.  The units were 
then sterilely connected to the ACP 215 standard 
disposable glycerolization kit (Haemonetics REF 
225, ACP 215 Red Cells Glycerolization Disposable 
Set, Haemonetics Corp.), and were glycerolized auto-
matically by the ACP 215 according to manufacturer’s 
procedure.  Once glycerolized, the units were cen-
trifuged and excess glycerol was expressed off.  The 
components were heat sealed in a polyester plastic 
bag to maintain sterility and were frozen.  The units 
were stored for at least 2 days at –65°C or less before 
deglycerolizing.  A more comprehensive description 
of the process using the ACP 215 can be found in a 
study by Valeri et al.9,10
Deglycerolization
The units were removed from the freezer and 
placed into a 37°C water bath until they reached a 
temperature of 32° ± 2°C.  Using the ACP 215 dis-
posable deglycerolization set (Haemonetics REF 235, 
ACP 215 Red Cells De-Glycerolization and Cell Wash 
Disposable Set, Haemonetics Corp.), the components 
were deglycerolized first with 12% saline followed by 
multiple large-volume washes using 0.9% saline con-
taining 0.2% glucose.  After washing was complete, 
the final product was resuspended in AS-3.  In-pro-
cess pressure checks at the end of deglycerolization 
indicated that the system remained closed and the 
units could retain a 14-day outdate.  As an additional 
indication of acceptability, a visual hemolysis check 
was performed on the waste supernatant using a 
color chart provided with the ACP 215 to ensure the 
free hemoglobin levels were less than 150 mg/dL.  A 
sample was taken for analysis of several variables in-
cluding analysis of the wash supernatant for plasma 
hemoglobin and osmolality.
Laboratory Analysis
At the time of the collection of the unit of whole 
blood, an additional tube of blood was drawn into 
EDTA for HbS analysis.  HbS was analyzed using ion-
exchange high-performance liquid chromatography 
(Varian HPLC system, Bio-Rad Diagnostics Group, 
Hercules, CA).
Before cryopreservation and after deglyceroliza-
tion of the RBC component, samples were taken for 
laboratory analysis and components were weighed for 
the calculation of the percent recovery of RBCs.  The 
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Fig. 1. A dark red, jelly-like mass in the bowl after deglycerolization.
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blood sample was used to test the hematocrit using 
a microhematocrit system (HemataStat II, Separation 
Technologies, Inc., Altamonte Springs, FL).  Plasma 
hemoglobin levels were also analyzed with a low-Hb 
photometer (HemoCue AB, Angelholm, Sweden).  An 
iSTAT (i-STAT Corporation, East Windsor, NJ) was 
used for measurement of blood gas analytes.
In addition, samples of the wash supernatant 
were analyzed for osmolality to ensure adequate 
removal of the glycerol.  Osmolality was performed 
using the method of freezing point depression on 
a microsample osmometer (Fiske 2400, Advanced 
Instruments Inc., Norwood, MA).
Statistics
Because of the relatively small sample size (n = 3), 
statistical analysis was not performed as significance 
could not be determined.
Results
Thawing and deglycerolization of all three RBC 
components from the donors with sickle cell trait 
resulted in the recovery of some RBCs (Table 1); 
however, the plasma hemoglobin level on the post-
deglycerolization supernatant sample from Donor 1 
was extremely high.  All components had acceptable 
osmolality levels of less than 400 mOsm/kg, indicat-
ing that glycerol removal was adequate.  Only the 
RBC component from Donor 2 passed the in-process 
pressure check indicating that the system remained 
closed during processing, conferring a 14-day out-
date.  A dark red, jelly-like mass was noted in the 
bowl after deglycerolization of all three components 
and was the largest for the component from Donor 
1 (Fig. 1).
The hematocrit levels of the deglycerolized com-
ponents ranged from 26 to 47 percent, and the RBC 
recoveries ranged from 43 to 76 percent.  The donors’ 
HbS levels ranged from 34 to 39 percent.  There ap-
peared to be no relationship between RBC recovery 
and the donors’ HbS levels (Table 1).  As expected, 
glucose and potassium levels in the RBC components 
decreased after deglycerolization and sodium levels 
increased (Table 2).  Washing removes approximately 
99 percent of plasma proteins, electrolytes, and anti-
bodies2 and exchanges residual CP2D for residual 
0.9% saline with 0.2% glucose.  In comparison, all six 
control RBC components collected from donors with-
out sickle cell trait had a postdeglycerolization RBC 
recovery of 80 percent or greater, an osmolality of 
less than 400 mOsm/kg, and hematocrit levels of 49 
percent or greater (Table 3).  Glucose, potassium, and 
sodium were not measured on the control units.
The sickle cell trait donors’ RBC components were 
all frozen 4 or 5 days after their collection and were 
stored for 4, 35, and 56 days before deglycerolization. 
RBCs from Donor 1 were cryopreserved the longest 
followed by Donors 2 and 3.  Future studies using 
the ACP 215 are needed to conclude whether there 
is a relationship between storage time and percent 
recovery after deglycerolization.
Table 1. Results of in vitro tests of RBC components before and after deglycerolization with the ACP 215
  Hct (%) HbS RBC Recovery  Supernatant Hgb (mg/dL) Color Check Osmolality
 Donor Before After (%) (%) Before After (<150 mg/dL) (mOsm/kg)
 1 64 26 34 43 150 1200 No 222
 2 67 47 38 76.5 130 480 Yes 212
 3 62 40 39 67.5 120 460 Yes 315
Table 2. Results of analysis of sickle cell trait RBC components before 
and after deglycerolization with the ACP 215
 Sodium Potassium Glucose 
 (mmol/L) (mmol/L) (mg/dL)
 Donor Before After Before After Before After
 1 118 131 >9.0 2.8 681 569
 2 122 130 >9.0 <2.0 662 542
 3 121 132 >9.0 <2.0 676 508
Table 3. Results of analysis of RBC components from donors without 
sickle cell trait that were cryopreserved and deglycerolized 
with the ACP 215
  Osmolality RBC Recovery Hct Color Check 
 Donor (mOsm/kg) (%) (%) (<150 mg/dL)
 1 304 92 52 Yes
 2 303 87 52 Yes
 3 297 85 52 Yes
 4 298 80 49 Yes
 5 304 84 51 Yes
 6 308 91 52 Yes
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Sickle cell trait donor blood
Discussion
An automated cell-processing system, APC 215, 
is available for the freezing and deglycerolization 
of RBC components and is being used to save 
rare donor units.  We tested this system using the 
manufacturer’s recommended procedures to process 
RBC components from donors with sickle cell trait 
to assess the feasibility of obtaining an acceptable 
cryopreserved and deglycerolized RBC component 
for transfusion.  RBC components from all three 
donors tested resulted in recovery of some RBCs. 
However, none of the deglycerolized components 
met the criteria for greater than 80 percent recov-
ery of RBCs, and congealed RBCs were noted in 
the bowl after the processing of each of the three 
components.  The process resulted in components 
that had osmolality levels that indicated the units 
were successfully deglycerolized, but it is not certain 
whether the posttransfusion recovery and survival of 
these components would be normal.
The mean of RBC recovery for our study was 62 
percent compared to 56 percent by Meryman and 
Hornblower7 using the traditional deglycerolization 
method and a manual cell washer.  The RBC recov-
ery with the ACP 215, however, was not as good as 
with the modified method for processing sickle cell 
trait donor RBC components described by Meryman 
and Hornblower7; mean recovery was 85 percent. 
We do not recommend that the standard ACP 215 
cryopreservation and deglycerolization methods be 
used for the routine processing of sickle cell trait 
donor RBCs, but it may be possible to modify the 
deglycerolization procedures used with the ACP 215 
method to improve the recovery of sickle cell trait 
RBCs.  Because hemolysis of sickle cell trait donor 
RBCs occurs in the deglycerolization process,7 modi-
fication of the ACP 215 deglycerolization solution may 
improve RBC recovery.  Perhaps greater dilution of 
the thawed RBCs with the solution containing 0.9% 
saline plus 0.2% glucose or increasing the pH of the 
deglycerolizing solutions11 would reduce hemolysis. 
Minimizing osmotic damage during glycerolization 
by adding glycerol more gradually through the use 
of additional steps may also be helpful.12
In conclusion, freezing and deglycerolization 
of sickle cell trait donor RBC components with the 
ACP 215 system resulted in better recovery than did 
the manual method, but it was not better than that 
produced by the modified method by Meryman and 
Hornblower.7  However, hemolysis and agglutination 
in the bowl were problematic.  Future modifications 
of the deglycerolization procedure using the ACP 215 
are needed for successful processing of sickle cell 
donor RBC components.
References
 1. Castro O, Sandler SG, Houston-Yu P, et al. 
Predicting the effect of transfusing only pheno-
type-matched RBCs to patients with sickle cell 
disease: theoretical and practical implications. 
Transfusion 2002;42:684–90.
 2. Brecher M. Technical Manual. 15th ed. Bethesda, 
MD: AABB Press, 2005;576,193.
 3. Osby M, Shulman I. Phenotype matching of do-
nor red blood cell units for nonalloimmunized 
sickle cell disease patients: a survey of 1182 
North American laboratories. Arch Pathol Lab 
Med 2005;129:190–3.
 4. Beattie KM, Shafer AW. Broadening the base 
of a rare donor program by targeting minority 
populations. Transfusion 1986;26:401–4.
 5. Gorlin JB, Adams CL, Stefan MM, Averbeck 
DA, Gonnella KC. Variable leukocyte reduction 
on units from donors with sickle cell trait: a 
time-temperature, donor reproducibility study 
(abstract). Transfusion 2000;40(Suppl):55.
 6. Stroncek DF, Rainer T, Sharon V, et al. Sickle Hb 
polymerization in RBC components from do-
nors with sickle cell trait prevents effective WBC 
reduction by filtration. Transfusion 2002;42: 
1466–72.
 7. Meryman HT, Hornblower M. Freezing and 
deglycerolizing sickle-trait red blood cells.
Transfusion 1976;16:627–32.
 8. Meryman HT, Hornblower M. A method for freez-
ing and washing red blood cells using a high 
glycerol concentration. Transfusion 1972;12: 
145–56.
 9. Valeri CR, Ragno G, Pivacek LE, et al. A multi-
center study of in vitro and in vivo values in 
human RBCs frozen with 40-percent (wt/vol) 
glycerol and stored after deglycerolization for 
15 days at 4 degrees C inAS-3: assessment of 
RBC processing in the ACP 215. Transfusion 
2001;41:933–9.
 10. Valeri CR, Ragno G, Pivacek L, et al. In vivo sur-
vival of apheresis RBCs, frozen with 40-percent 
(wt/vol) glycerol, deglycerolized in theACP 215, 
and stored at 4 degrees C in AS-3 for up to 21 
days. Transfusion 2001;41:928–32.
112 I M M U N O H E M AT O L O G Y,  V O L U M E  2 4 ,  N U M B E R  3 ,  2 0 0 8
 11. Rivers SL, Liles B. Problems associated with 
freezing and thawing of red blood cells con-
taining AS hemoglobin (abstract). Transfusion 
1973;13:356.
 12. Valeri CR, Lindberg JR, Contreras TJ, et al. Freeze 
preserved baboon red blood cells: effects of 
biochemical modification and perfusion in vitro. 
Am J Vet Res 1981;42:1590–4.
Ricci Jo Ackley, MT(ASCP)SBB, Interim Manager, 
George Washington University Hospital, Transfusion 
Medicine, Washington, DC, A. Hallie Lee-Stroka, 
MT(ASCP)SBB, Technical Specialist, National 
r.J. acKley et al.
Institutes of Health, Department of Transfusion 
Medicine, Clinical Center, Barbara J. Bryant, MD, 
MT(ASCP)SBB, Staff Physician, National Institutes of 
Health, Department of Transfusion Medicine, Clinical 
Center, David F. Stroncek, MD, Chief, Laboratory 
Services Section, National Institutes of Health, 
Department of Transfusion Medicine, Clinical Center, 
and Karen M. Byrne, MDE, MT(ASCP)SBB, (corre-
sponding author) Education Coordinator, National 
Institutes of Health, Department of Transfusion 
Medicine, Clinical Center, 10 Center Drive MSC 1184, 
Bethesda, MD 20892-1184.
Notice to Readers: All articles published, 
including communications and book reviews, 
reflect the opinions of the authors and do not 
necessarily reflect the official policy of the 
American Red Cross.
Attention: State Blood Bank Meeting Organizers
If you are planning a state meeting and would like copies of Immunohematology for distribution, please 
contact Cindy Flickinger, Managing Editor, 4 months in advance, by fax or e-mail at (215) 451-2538 or 
flickingerc@usa.redcross.org.
